Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: Pathogenesis and therapeutic prospective

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 4, 2006, Pages 353-360

  Abassi, Zaid ^a   Nakhoul, Farid ^a,b   Khankin, Eliyahu ^a,b   Reisner, Shimon A ^b   Yigla, Mordechai ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Rambam Health Care Campus ^*  (Israel)

^c Division of Pulmonary Medicine   (Israel)

Author keywords

Arteriovenous access; Calcification; Cardiac output; End stage renal disease; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CALCIUM ANTAGONIST; DIGOXIN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILEOPROST; NITRIC OXIDE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNIPROST; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANEMIA; ARTERIOVENOUS FISTULA; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIALYSIS; DOPPLER ECHOCARDIOGRAPHY; HEART OUTPUT; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; LUNG ARTERY PRESSURE; LUNG CALCIFICATION; LUNG VASCULAR RESISTANCE; MORBIDITY; MORTALITY; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BLOOD PRESSURE; CALCINOSIS; CARDIAC OUTPUT; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY ARTERY; RENAL DIALYSIS; TIME FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 33748081757     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000232874.27846.37     Document Type: Review

References (42)

1. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis 1988; 31:205-238.
2. Archer S, Rich S. Primary pulmonary hypertension. A vascular biology and translational research 'work in progress' Circulation 2000; 102:2781-2791.
3. Yigla M, Dabbah S, Azzam ZS, et al. Background diseases in 671 patients with moderate to severe pulmonary hypertension. Israel Med Assoc J 2000; 2:684-689.
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
5. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886-895.
6. Heath D, Smith P, Gosney J, et al. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 1987; 58:555-558.
7. Rubin LJ. Pathology and patho-physiology of primary pulmonary hypertension. Am J Cardiol 1995; 75:51A-54A.
8. Jeffery TK, Morrel LW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45:173-202.
9. Bossone E, Bodini BD, Mazza A, et al. Pulmonary arterial hypertension: the key role echocardiography. Chest 2005; 127:1836-1843.
10. Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123:1577-1582.
11. Reisner SA, Azzam Z, Halmann M, et al. Septal to free wall curvature ratio: a non-invasive index of pulmonary arterial pressure. J Am Soc Echo 1994; 7:27-35.
12. Ihlen H, Endresen K, Golf S, et al. Cardiac stroke volume during exercise measured by Doppler echocardiography: comparison with the thermo-dilution technique and evaluation of reproducibility. Br Heart J 1987; 58:455-459.
13. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uremia. Nephrol Dial Transplant 2000; 15:1194-1200.
14. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin 1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114:464-469.
15. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000; 320:223-232.
16. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with primary pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.
17. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000; 13:96-105.
18. Giaid A. NO and endothelin-1 in pulmonary hypertension. Chest 1998; 114 (Suppl 3):208S-212S.
19. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001; 60:472-479.
20. Conger JD, Hammond WS, Alfery AC, et al. Pulmonary calcification in chronic dialysis patients: clinical and pathologic studies. Ann Intern Med 1975; 83:330-336.
21. Amin M, Fawzy A, Abdel Hamid M, Elhendy A. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 2003; 124:2093-2097.
22. Brooks DP. Role of endothelin in renal function and dysfunction. Clin Exp Pharmacol Physiol 1996; 23:345-348.
23. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Abnormalities of endothelial function in patients with pre-dialysis renal failure. Heart 2000; 83:205-209.
24. Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19:1168-1172.
25. Young PR, Rohr MS, Marterre WF. High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula. Am Surg 1998; 64:239-241.
26. Savage MT, Ferro CJ, Sassano A, Tomson CR. The impact of arteriovenous fistula formation on central hemo-dynamic pressures in chronic renal failure patients: a prospective study. Am J Kidney Dis 2002; 40:753-759.
27. Okura H, Takatsu Y. High output failure as cause of pulmonary hypertension. Intern Med 1994; 33:363-365.
28. Clarkson MR, Giblin L, Brown A, et al. Reversal of pulmonary hypertension after ligation of a barachiocephalic arteriovenous fistula. Am J Kidney Dis 2002; 40:1-4.
29. Unger P, Velez-Roa S, Wissing KM, et al. Regression of left ventricular hypertrophy after arterio-venous fistula closure in renal transplant recipient: a long-term follow-up. Am J Transplant 2004; 4:2038-2044.
30. MacRae JM, Pandeya S, Humen DP, et al. Arteriovenous fistula-associated high-output failure: a review of mechanism. Am J Kidney Dis 2004; 43:e17-e22.
31. Giaid A, Saleh D. Reduced expression of the endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-221.
32. Stamler JS, Loh E, Roddy M-A, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89:2035-2040.
33. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38 (4 Suppl 1):S74-S79.
34. Harrison WF, Farber HW, Loscalzo J. Pulmonary arterial hypertension: mechanism of disease. N Engl J Med 2004; 351:1655-1665.
35. Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20:1686-1692.
36. Rabelink TJ, Koomans HA. Endothelial function and the kidney: an emerging target for cardiovascular therapy. Drugs 1997; 53 (Suppl 1):S11-S19.
37. Rubin LJ, Badesch DB, Barst RJ, et al. Bosantan therapy for pulmonary hypertension. N Engl J Med 2002; 346:896-903.
38. Humbert M, Olivier S, Gerald S. Treatment of pulmonary arterial hypertension: drug therapy. N Engl J Med 2004; 351:1425-1436.
39. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005; 258:199-215.
40. Rubin LJ, Badesch DB, Barst RJ, et al. Bosantan therapy for pulmonary hypertension. N Engl J Med 2002; 346:896-903.
41. Liefeldt L, van Giersbergen PL, Dingemanse J, et al. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am J Kidney Dis 2004; 43:923-926.
42. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157.